These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34333552)

  • 21. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells.
    Ota T; Doi K; Fujimoto T; Tanaka Y; Ogawa M; Matsuzaki H; Kuroki M; Miyamoto S; Shirasawa S; Tsunoda T
    Anticancer Res; 2012 Jun; 32(6):2271-5. PubMed ID: 22641662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.
    Roda D; Castillo J; Telechea-Fernández M; Gil A; López-Rodas G; Franco L; González-Rodríguez P; Roselló S; Pérez-Fidalgo JA; García-Trevijano ER; Cervantes A; Zaragozá R
    PLoS One; 2015; 10(6):e0130543. PubMed ID: 26110767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
    Amankwatia EB; Chakravarty P; Carey FA; Weidlich S; Steele RJ; Munro AJ; Wolf CR; Smith G
    Br J Cancer; 2015 Apr; 112(9):1480-90. PubMed ID: 25919696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.
    Fan C; Lin Y; Mao Y; Huang Z; Liu AY; Ma H; Yu D; Maitikabili A; Xiao H; Zhang C; Liu F; Luo Q; Ouyang G
    Oncotarget; 2016 Apr; 7(16):21825-39. PubMed ID: 26968810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
    Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic
    Boutin AT; Liao WT; Wang M; Hwang SS; Karpinets TV; Cheung H; Chu GC; Jiang S; Hu J; Chang K; Vilar E; Song X; Zhang J; Kopetz S; Futreal A; Wang YA; Kwong LN; DePinho RA
    Genes Dev; 2017 Feb; 31(4):370-382. PubMed ID: 28289141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
    Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
    J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.
    Pelullo M; Nardozza F; Zema S; Quaranta R; Nicoletti C; Besharat ZM; Felli MP; Cerbelli B; d'Amati G; Palermo R; Capalbo C; Talora C; Di Marcotullio L; Giannini G; Checquolo S; Screpanti I; Bellavia D
    Cancer Res; 2019 Nov; 79(21):5575-5586. PubMed ID: 31506332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
    Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
    Trinidad AG; Whalley N; Rowlinson R; Delpuech O; Dudley P; Rooney C; Critchlow SE
    Oncogene; 2017 Nov; 36(44):6164-6176. PubMed ID: 28692044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
    Morkel M; Riemer P; Bläker H; Sers C
    Oncotarget; 2015 Aug; 6(25):20785-800. PubMed ID: 26299805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
    Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
    Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.